Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Six brokerages give Enliven a consensus rating of "Moderate Buy" (five buy, one sell), with an average 12‑month price target of $43.40.
• Company insiders have been net sellers recently — the CFO sold 10,000 shares at $29.58 and insiders disposed of 37,460 shares (~$1.04M) in the last quarter, while insiders still hold 25.90% of the stock.
• Enliven is a clinical‑stage biotech focused on induced‑proximity molecular glues; it reported a quarterly EPS loss of $0.48 (missing estimates), trades with a $2.71B market cap, and has a one‑year price range of $14.45–$46.31.

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $43.40.

ELVN has been the topic of a number of research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. HC Wainwright lifted their target price on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a "buy" rating in a research note on Thursday, March 26th. Mizuho lifted their target price on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an "outperform" rating in a research note on Wednesday, March 25th. Finally, Wall Street Zen lowered shares of Enliven Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 28th.

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 10,000 shares of the business's stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the sale, the chief financial officer owned 51,000 shares of the company's stock, valued at $1,508,580. The trade was a 16.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard A. Heyman sold 1,230 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the sale, the director directly owned 22,647 shares in the company, valued at $592,898.46. The trade was a 5.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 37,460 shares of company stock valued at $1,041,104 over the last quarter. Corporate insiders own 25.90% of the company's stock.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock worth $44,000 after acquiring an additional 594 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after acquiring an additional 930 shares in the last quarter. Quantbot Technologies LP boosted its stake in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock worth $90,000 after acquiring an additional 1,434 shares in the last quarter. AlphaQuest LLC bought a new stake in Enliven Therapeutics during the third quarter worth about $96,000. Finally, Tower Research Capital LLC TRC boosted its stake in Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock worth $106,000 after acquiring an additional 3,490 shares in the last quarter. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Trading Down 0.6%

Shares of ELVN opened at $45.32 on Friday. The firm's 50-day moving average price is $31.44 and its 200-day moving average price is $24.49. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of -24.37 and a beta of 0.26. Enliven Therapeutics has a 1-year low of $14.45 and a 1-year high of $46.31.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). On average, research analysts forecast that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.